Lisinopril interactions with other drugs
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Lisinopril Interactions with Other Drugs
Lisinopril and Metformin Interaction
Lisinopril, an ACE inhibitor, shows significant interactions with metformin, a common antidiabetic drug. Studies have demonstrated that when lisinopril and metformin are co-administered, there is a notable impact on the dissolution profiles of both drugs. Specifically, the presence of lisinopril decreases the percentage of metformin released at various pH levels (1.2, 4.5, and 6.8). Conversely, metformin increases the percentage of lisinopril released at pH 1.2 and 6.8, but not at pH 4.5. These interactions suggest that the co-administration of these drugs could potentially alter their therapeutic efficacy and necessitate careful monitoring and possible dose adjustments.
Lisinopril and Gliclazide Interaction
In patients with type II diabetes and hypertension, the combination of lisinopril and gliclazide, a sulfonylurea, has been shown to produce significant drug-drug interactions. Chronic use of lisinopril enhances the blood glucose-lowering effect of gliclazide in both normal and diabetic rats. This interaction suggests that when these drugs are used together, there may be a need for dose adjustments to avoid hypoglycemia. The study highlights the importance of monitoring blood glucose levels closely in patients receiving this combination therapy.
Lisinopril and Diclofenac Sodium Interaction
The combination of lisinopril and diclofenac sodium, a nonsteroidal anti-inflammatory drug (NSAID), can reduce the antihypertensive efficacy of lisinopril. This interaction is observed in both diabetic and non-diabetic hypertensive patients with osteoarthritis. Additionally, the combination treatment can lead to increased serum creatinine levels and altered renal function markers such as creatinine clearance and blood urea nitrogen (BUN). These findings underscore the need for careful management and monitoring of blood pressure and renal function in patients receiving both lisinopril and diclofenac sodium.
Lisinopril and Nifedipine Interaction
A study investigating the interaction between lisinopril and nifedipine, a calcium channel blocker, found no significant pharmacokinetic or pharmacodynamic interactions between the two drugs when administered as single oral doses. The combination of these drugs showed additive effects on blood pressure reduction without altering the pharmacokinetics of either drug. This suggests that lisinopril and nifedipine can be co-administered without significant concerns for drug-drug interactions.
Lisinopril and Hydrochlorothiazide Interaction
The co-administration of lisinopril and hydrochlorothiazide, a thiazide diuretic, has been shown to have no clinically relevant pharmacokinetic interactions. Studies indicate that the peak serum levels and urinary recovery of both drugs remain largely unaffected when administered together, either as separate tablets or in a fixed-dose combination. This supports the use of this combination in the treatment of hypertension without the need for dose adjustments due to pharmacokinetic concerns.
Lisinopril and JBP485 Interaction
Lisinopril interacts with JBP485, a dipeptide with antihepatitis activity, through shared transport mechanisms in the intestine and kidneys. When administered together, the plasma concentrations of both drugs decrease significantly due to competition for the peptide cotransporter 1 (PEPT1) in the intestine and organic anion transporters (OATs) in the kidneys. This interaction highlights the importance of considering transporter-mediated drug-drug interactions when co-administering these medications.
Conclusion
Lisinopril interacts with various drugs through different mechanisms, including alterations in dissolution profiles, enhanced pharmacodynamic effects, and competition for transporters. These interactions can impact the therapeutic efficacy and safety of the drugs involved, necessitating careful monitoring and potential dose adjustments. Understanding these interactions is crucial for optimizing treatment regimens and ensuring patient safety.
Sources and full results
Most relevant research papers on this topic